Literature DB >> 34309124

Effects of participation in a U.S. trial of newborn genomic sequencing on parents at risk for depression.

Talia S Schwartz1,2,3, Kurt D Christensen4,5,6, Melissa K Uveges7,8, Susan E Waisbren1,6, Amy L McGuire9, Stacey Pereira9, Jill O Robinson9, Alan H Beggs1,2,6, Robert C Green5,6,7, Gloria A Bachmann3, Arnold B Rabson3, Ingrid A Holm1,2,6.   

Abstract

Much emphasis has been placed on participant's psychological safety within genomic research studies; however, few studies have addressed parental psychological health effects associated with their child's participation in genomic studies, particularly when parents meet the threshold for clinical concern for depression. We aimed to determine if parents' depressive symptoms were associated with their child's participation in a randomized-controlled trial of newborn exome sequencing. Parents completed the Edinburgh Postnatal Depression Scale (EPDS) at baseline, immediately post-disclosure, and 3 months post-disclosure. Mothers and fathers scoring at or above thresholds for clinical concern on the EPDS, 12 and 10, respectively, indicating possible Major Depressive Disorder with Peripartum Onset, were contacted by study staff for mental health screening. Parental concerns identified in follow-up conversations were coded for themes. Forty-five parents had EPDS scores above the clinical threshold at baseline, which decreased by an average of 2.9 points immediately post-disclosure and another 1.1 points 3 months post-disclosure (both p ≤ .014). For 28 parents, EPDS scores were below the threshold for clinical concern at baseline, increased by an average of 4.7 points into the elevated range immediately post-disclosure, and decreased by 3.8 points at 3 months post-disclosure (both p < .001). Nine parents scored above thresholds only at 3 months post-disclosure after increasing an average of 5.7 points from immediately post-disclosure (p < .001). Of the 82 parents who scored above the threshold at any time point, 43 (52.4%) were reached and 30 (69.7%) of these 43 parents attributed their elevated scores to parenting stress, balancing work and family responsibilities, and/or child health concerns. Only three parents (7.0%) raised concerns about their participation in the trial, particularly their randomization to the control arm. Elevated scores on the EPDS were typically transient and parents attributed their symptomatology to life stressors in the postpartum period rather than participation in a trial of newborn exome sequencing.
© 2021 National Society of Genetic Counselors.

Entities:  

Keywords:  exome sequencing; mental health; newborn screening; parents; pediatrics; psychosocial

Mesh:

Year:  2021        PMID: 34309124      PMCID: PMC8789951          DOI: 10.1002/jgc4.1475

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  36 in total

1.  Subconstructs of the Edinburgh Postnatal Depression Scale in a multi-ethnic inner-city population in the U.S.

Authors:  Yueh-Hsiu Mathilda Chiu; Perry E Sheffield; Hsiao-Hsien Leon Hsu; Jonathan Goldstein; Paul C Curtin; Rosalind J Wright
Journal:  Arch Womens Ment Health       Date:  2017-08-02       Impact factor: 3.633

2.  ACOG Committee Opinion No. 757: Screening for Perinatal Depression.

Authors: 
Journal:  Obstet Gynecol       Date:  2018-11       Impact factor: 7.661

3.  Using the Edinburgh Postnatal Depression Scale for women and men-some cautionary thoughts.

Authors:  Stephen Matthey; Francesca Agostini
Journal:  Arch Womens Ment Health       Date:  2017-01-11       Impact factor: 3.633

4.  Sequencing Newborns: A Call for Nuanced Use of Genomic Technologies.

Authors:  Josephine Johnston; John D Lantos; Aaron Goldenberg; Flavia Chen; Erik Parens; Barbara A Koenig
Journal:  Hastings Cent Rep       Date:  2018-07       Impact factor: 2.683

Review 5.  Incorporating Recognition and Management of Perinatal Depression Into Pediatric Practice.

Authors:  Marian F Earls; Michael W Yogman; Gerri Mattson; Jason Rafferty
Journal:  Pediatrics       Date:  2019-01       Impact factor: 7.124

6.  Perceived Benefits, Risks, and Utility of Newborn Genomic Sequencing in the BabySeq Project.

Authors:  Stacey Pereira; Jill Oliver Robinson; Amanda M Gutierrez; Devan K Petersen; Rebecca L Hsu; Caroline H Lee; Talia S Schwartz; Ingrid A Holm; Alan H Beggs; Robert C Green; Amy L McGuire
Journal:  Pediatrics       Date:  2019-01       Impact factor: 7.124

7.  Interpretation of Genomic Sequencing Results in Healthy and Ill Newborns: Results from the BabySeq Project.

Authors:  Ozge Ceyhan-Birsoy; Jaclyn B Murry; Kalotina Machini; Matthew S Lebo; Timothy W Yu; Shawn Fayer; Casie A Genetti; Talia S Schwartz; Pankaj B Agrawal; Richard B Parad; Ingrid A Holm; Amy L McGuire; Robert C Green; Heidi L Rehm; Alan H Beggs
Journal:  Am J Hum Genet       Date:  2019-01-03       Impact factor: 11.025

8.  The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine.

Authors:  Jason L Vassy; Denise M Lautenbach; Heather M McLaughlin; Sek Won Kong; Kurt D Christensen; Joel Krier; Isaac S Kohane; Lindsay Z Feuerman; Jennifer Blumenthal-Barby; J Scott Roberts; Lisa Soleymani Lehmann; Carolyn Y Ho; Peter A Ubel; Calum A MacRae; Christine E Seidman; Michael F Murray; Amy L McGuire; Heidi L Rehm; Robert C Green
Journal:  Trials       Date:  2014-03-20       Impact factor: 2.279

9.  Developing a common framework for evaluating the implementation of genomic medicine interventions in clinical care: the IGNITE Network's Common Measures Working Group.

Authors:  Lori A Orlando; Nina R Sperber; Corrine Voils; Marshall Nichols; Rachel A Myers; R Ryanne Wu; Tejinder Rakhra-Burris; Kenneth D Levy; Mia Levy; Toni I Pollin; Yue Guan; Carol R Horowitz; Michelle Ramos; Stephen E Kimmel; Caitrin W McDonough; Ebony B Madden; Laura J Damschroder
Journal:  Genet Med       Date:  2017-09-14       Impact factor: 8.822

10.  Disclosing genetic risk for Alzheimer's dementia to individuals with mild cognitive impairment.

Authors:  Kurt D Christensen; Jason Karlawish; J Scott Roberts; Wendy R Uhlmann; Kristin Harkins; Elisabeth M Wood; Thomas O Obisesan; Lan Q Le; L Adrienne Cupples; Emilie S Zoltick; Megan S Johnson; Margaret K Bradbury; Leo B Waterston; Clara A Chen; Sara Feldman; Denise L Perry; Robert C Green
Journal:  Alzheimers Dement (N Y)       Date:  2020-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.